Trillium Therapeutics Inc.

The top biopharma companies are spending more on R&D than they did 10 years ago as a percentage of sales but even with investment, R&D productivity will not offset a looming patent cliff that begins i

Roche Holding AG , Genentech, Inc. and their affiliated companies were the busiest deal makers in the biopharmaceutical sector for the second consecutive year in 2021, with 23 deals across all cate

Merck & Co., Inc. is giving the US Federal Trade Commission more time to review its $11.5bn all-cash acquisition of Acceleron Pharma, Inc. in a move that also extends the deadline for Acceleron inv

Investor interest in initial public offerings in the US by biopharmaceutical companies apparently has not abated in the new year, with two oncology-focused firms – Cullinan Management Inc. and Gracel